Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | PDE9A | O76083 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | GPR6 | P46095 | 4/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128714 | 0.89 | CYP3A4 (0.61) | GPR119CYP3A4CYP2C9IRAK4 | |
| SCHEMBL4355956 | 0.86 | CYP3A4 (0.57) | GPR119CYP3A4PDE9ACYP2C9CYP11B1 | |
| SCHEMBL4358909 | 0.85 | CYP3A4 (0.50) | GPR119CYP3A4PDE9ACYP2C9FLT3 | |
| SCHEMBL4468923 | 0.85 | CYP3A4 (0.47) | GPR119CYP3A4CYP2C9FLT3 | |
| SCHEMBL4368392 | 0.85 | CYP3A4 (0.51) | GPR119CYP3A4PDE9ACYP2C9 | |
| SCHEMBL1129187 | 0.84 | CYP3A4 (0.61) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL4328580 | 0.84 | CYP3A4 (0.51) | GPR119CYP3A4PDE9ACYP2C9FLT3 | |
| SCHEMBL1128285 | 0.84 | CYP3A4 (0.48) | GPR119CYP3A4CYP2C9FLT3 | |
| SCHEMBL4357229 | 0.83 | CYP3A4 (0.47) | GPR119CYP3A4PDE9ACYP2C9 | |
| SCHEMBL4359029 | 0.83 | CYP3A4 (0.47) | GPR119CYP3A4PDE9ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | GPR119 1/4885CYP3A4 1503/4885PDE9A 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.